Stay updated with breaking news from Geneuro porteur. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
> Nachricht GeNeuro Completes Patient Recruitment in Temelimab Phase 2 Multiple Sclerosis Trial at the Karolinska Institutet’s Academic Specialist Center (ASC) Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced the completed patient recruitment in its Phase 2 trial of temelimab in MS patients, conducted at the Karolinska Institutet’s Academic Specialist Center (ASC), in Stockholm (Sweden). Temelimab is a monoclonal antibody designed to neutralize a pathogenic retroviral envelope protein, pHERV-W Env. The study, called ProTEct-MS, has enrolled a very homogenous cohort of 42 patients being treated with temelimab (18, 36 and 54mg/kg) vs. placebo and evaluated for 48 weeks. The patients included in ....
GeNeuro Receives French State Grant to Accelerate Research Into the Role of HERV Proteins in COVID-19 wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.